The extracorporeal membrane oxygenation market size is projected to reach US$ 0.74 billion by 2031 from US$ 0.58 billion in 2023. The market is expected to register a CAGR of 3.10% during 2023–2031. Surging product developments and approvals will likely remain a key trend in the market.
In 2020, there were 89.1 million cases of ischemic stroke and 68.2 million cases of stroke worldwide. In North America, there are more cases of cardiovascular disease. Globally, heart diseases are becoming more prevalent, with developed nations seeing a sharp rise in their incidence. Changes in lifestyle and other health issues are contributing to an increase in the incidences. The market is expected to grow due to new product releases, technological advancements, and the prevalence of a large population at risk for cardiovascular illnesses. Players like Terumo Group, Medtronic Plc, MicroPort Scientific Corporation, LivaNova Plc, Nioro Medical Corporation, Getinge AB, Braile Biomedica, Fresenius Medical Care AG & Co KGaA, Abiomed Inc., and others make up the majority of the extracorporeal membrane oxygenation (ECMO) market.
Respiratory failure may result from airflow obstruction brought on by chronic obstructive pulmonary disease (COPD). It is among the severe illnesses that kill millions of people worldwide. The World Health Organization (WHO) reports that 3.23 million people worldwide died from COPD in 2019, making it the third most common cause of death in 2022. Roughly 90% of deaths from COPD take place in low- and middle-income nations. In 2020, COPD ranked as the sixth most common cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC). Therefore, the market for ECMOs is growing due to the rising prevalence of respiratory failures and cardiovascular diseases.
For patients with end-stage lung diseases like cystic fibrosis, idiopathic pulmonary fibrosis (IPF), and COPD, lung transplantation is a life-saving treatment option that can enhance quality of life. ECMO is a flexible instrument utilized during the preoperative, intraoperative, and postoperative stages of lung transplantation. It serves as a transitional period for patients receiving lung transplants. As a result, the use of ECMO in lung transplantation is expanding quickly to treat patients whose lung disease poses a serious threat to their lives. The Scientific Registry of Transplant Recipients (SRTR) reports that approximately 4,600 lung transplants are carried out annually worldwide, with North America accounting for 55% of those procedures. The same source states that in the US, 3,243 patients were added to the waiting list, and approximately 2,759 patients received lung transplants. Following a lung transplant, the most common cause of death is primary graft dysfunction (PGD).
Thus, PGD following lung transplantation is treated penultimately with ECMO. The overall incidence of PGD, according to the National Library of Medicine (NLM) in 2022, is 30%. Risk factors for this condition include organ acquisition, preservation methods, intraoperative organ implantation and reperfusion, and preoperative donor lung ischemia. As a result, there is an increasing need for ECMO equipment to treat PGD patients.
Since ECMO treatments have encouraged survival rates, the use of ECMO for treating respiratory failure has increased recently. In 2021, a study by BioMed Central reported that patients with COVID-19 who experienced respiratory failure and received veno-venous extracorporeal membrane oxygenation (V-V ECMO) had a 60% survival rate. Furthermore, because it improves patient survival rates, ECMO is advised for patients with acute respiratory distress syndrome (ADRS), primary graft dysfunction following lung transplantation, and lung trauma. Additionally, ECMO improves the survival rate of patients whose post-cardiac arrest regimen is impacted. A radical change in the adoption of Westernized lifestyles causes several cardiac conditions. This prompts the major players to make significant R&D investments, which enhances the effectiveness of ECMO treatment and raises the survival rate. As a result, more market opportunities are anticipated during the forecast period due to the increasing survival rate of using ECMO in various treatments.
Key segments that contributed to the derivation of the extracorporeal membrane oxygenation market analysis are modality, application, and age group.
The geographic scope of the extracorporeal membrane oxygenation market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The North America extracorporeal membrane oxygenation market is segmented into the US, Canada, and Mexico. The presence of essential market players and a growing number of product launches and approvals are vital factors responsible for market growth in the region. Also, the increasing prevalence of cardiovascular diseases and respiratory diseases is likely to favor market growth
The regional trends and factors influencing the Extracorporeal Membrane Oxygenation Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Extracorporeal Membrane Oxygenation Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 0.58 Billion |
| Market Size by 2031 | US$ 0.74 Billion |
| Global CAGR (2023 - 2031) | 3.10% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Modality
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Extracorporeal Membrane Oxygenation Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Extracorporeal Membrane Oxygenation Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The extracorporeal membrane oxygenation market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the extracorporeal membrane oxygenation market are listed below:
The “Extracorporeal Membrane Oxygenation Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
The market is expected to register a CAGR of 3.10% during 2023–2031.
Terumo Group, Medtronic Plc, Braile Biomedica, LivaNova Plc, Nipro Medical Corporation, MicroPort Scientific Corporation, Eurosets S.R.L., Getinge AB, Fresenius Medical Care AG & Co KGaA
Surging product developments and approvals will likely remain a key trend in the market.
Key factors driving the market are the increasing prevalence of cardiovascular diseases and respiratory failures and the growing adoption of ECMO in lung transplantation procedures.
North America dominated the extracorporeal membrane oxygenation market in 2023